<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">24566651</PMID>
      <DateCompleted>
        <Year>2014</Year>
        <Month>12</Month>
        <Day>18</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>31</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1488-2329</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>186</Volume>
            <Issue>15</Issue>
            <PubDate>
              <Year>2014</Year>
              <Month>Oct</Month>
              <Day>21</Day>
            </PubDate>
          </JournalIssue>
          <Title>CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne</Title>
          <ISOAbbreviation>CMAJ</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Sjögren syndrome.</ArticleTitle>
        <Pagination>
          <StartPage>E579</StartPage>
          <EndPage>E586</EndPage>
          <MedlinePgn>E579-86</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1503/cmaj.122037</ELocationID>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Mavragani</LastName>
            <ForeName>Clio P</ForeName>
            <Initials>CP</Initials>
            <AffiliationInfo>
              <Affiliation>Departments of Physiology (Mavragani) and Pathophysiology (Moutsopoulos), Faculty of Medicine, University of Athens, Athens, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Moutsopoulos</LastName>
            <ForeName>Haralampos M</ForeName>
            <Initials>HM</Initials>
            <AffiliationInfo>
              <Affiliation>Departments of Physiology (Mavragani) and Pathophysiology (Moutsopoulos), Faculty of Medicine, University of Athens, Athens, Greece hmoutsop@med.uoa.gr.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2014</Year>
          <Month>02</Month>
          <Day>24</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>CMAJ</MedlineTA>
        <NlmUniqueID>9711805</NlmUniqueID>
        <ISSNLinking>0820-3946</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012859" MajorTopicYN="Y">Sjogren's Syndrome</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2014</Year>
          <Month>2</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2014</Year>
          <Month>2</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>12</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">24566651</ArticleId>
        <ArticleId IdType="pmc">PMC4203623</ArticleId>
        <ArticleId IdType="doi">10.1503/cmaj.122037</ArticleId>
        <ArticleId IdType="pii">cmaj.122037</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Mavragani CP, Moutsopoulos HM. The geoepidemiology of Sjögren’s syndrome. Autoimmun Rev
2010;9:A305-10</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19903539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Routsias JG, Tzioufas AG. Autoimmune response and target autoantigens in Sjögren’s syndrome. Eur J Clin Invest
2010;40: 1026–36</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20629708</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoshimi R, Ueda A, Ozato K, et al. . Clinical and pathological roles of Ro/SSA autoantibody system. Clin Dev Immunol. 2012; 2012:606195.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3523155</ArticleId>
            <ArticleId IdType="pubmed">23304190</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drosos AA, Andonopoulos AP, Costopoulos JS, et al. . Prevalence of primary Sjögren’s syndrome in an elderly population. Br J Rheumatol
1988;27:123–7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3365531</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haugen AJ, Peen E, Hulten B, et al. . Estimation of the prevalence of primary Sjögren’s syndrome in two age-different community-based populations using two sets of classification criteria: the Hordaland Health Study. Scand J Rheumatol
2008;37:30–4</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18189192</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Voulgarelis M, Ziakas PD, Papageorgiou A, et al. . Prognosis and outcome of non-Hodgkin lymphoma in primary Sjögren syndrome. Medicine (Baltimore)
2012;91:1–9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22198497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skopouli FN, Dafni U, Ioannidis JP, et al. . Clinical evolution, and morbidity and mortality of primary Sjögren’s syndrome. Semin Arthritis Rheum
2000;29:296–304</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10805354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Malladi AS, Sack KE, Shiboski S, et al. . Primary Sjögren’s syndrome as a systemic disease: a study of participants enrolled in an international Sjögren’s syndrome registry. Arthritis Care Res (Hoboken). 2012; 64:911–8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3595164</ArticleId>
            <ArticleId IdType="pubmed">22238244</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren’s syndrome. Arthritis Rheum
2002; 46:741–7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11920410</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sumida T, Tsuboi H, Iizuka M, et al. . Anti-M3 muscarinic acetylcholine receptor antibodies in patients with Sjögren’s syndrome. Mod Rheumatol
2013;23:841–5</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23135882</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skopouli FN, Papanikolaou S, Malamou-Mitsi V, et al. . Obstetric and gynaecological profile in patients with primary Sjögren’s syndrome. Ann Rheum Dis
1994;53:569–73</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1005407</ArticleId>
            <ArticleId IdType="pubmed">7979594</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skopouli FN, Talal A, Galanopoulou V, et al. . Raynaud’s phenomenon in primary Sjögren’s syndrome. J Rheumatol
1990;17:618–20</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2359071</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ng WF, Bowman SJ. Primary Sjögren’s syndrome: too dry and too tired. Rheumatology (Oxford)
2010;49:844–53</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20147445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skopouli FN, Barbatis C, Moutsopoulos HM. Liver involvement in primary Sjögren’s syndrome. Br J Rheumatol
1994;33:745–8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8055202</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goules A, Masouridi S, Tzioufas AG, et al. . Clinically significant and biopsy-documented renal involvement in primary Sjögren syndrome. Medicine (Baltimore)
2000;79:241–9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10941353</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mavragani CP, Fragoulis GE, Moutsopoulos HM. Endocrine alterations in primary Sjögren’s syndrome: an overview. J Autoimmun
2012;39:354–8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22695186</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mavragani CP, Schini M, Gravani F, et al. . Brief report: adrenal autoimmunity in primary Sjögren’s syndrome. Arthritis Rheum
2012;64:4066–71</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22933251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Euthymiopoulou K, Aletras AJ, Ravazoula P, et al. . Antiovarian antibodies in primary Sjögren’s syndrome. Rheumatol Int
2007; 27:1149–55</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17541596</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsokos M, Lazarou SA, Moutsopoulos HM. Vasculitis in primary Sjögren’s syndrome. Histologic classification and clinical presentation. Am J Clin Pathol
1987;88:26–31</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3604987</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ramos-Casals M, Anaya JM, Garcia-Carrasco M, et al. . Cutaneous vasculitis in primary Sjögren syndrome: classification and clinical significance of 52 patients. Medicine (Baltimore)
2004;83:96–106</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15028963</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brito-Zerón P, Akasbi M, Bosch X, et al. . Classification and characterisation of peripheral neuropathies in 102 patients with primary Sjögren’s syndrome. Clin Exp Rheumatol
2013;31:103–10</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23020902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pavlakis PP, Alexopoulos H, Kosmidis ML, et al. . Peripheral neuropathies in Sjögren syndrome: a new reappraisal. J Neurol Neurosurg Psychiatry
2011;82:798–802</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21172862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alexander EL, Arnett FC, Provost TT, et al. . Sjögren’s syndrome: association of anti-Ro(SS-A) antibodies with vasculitis, hematologic abnormalities, and serologic hyperreactivity. Ann Intern Med
1983;98:155–9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6600593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soliotis FC, Mavragani CP, Moutsopoulos HM. Central nervous system involvement in Sjögren’s syndrome. Ann Rheum Dis
2004; 63:616–20</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1755013</ArticleId>
            <ArticleId IdType="pubmed">15140765</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsampoulas CG, Skopouli FN, Sartoris DJ, et al. . Hand radiographic changes in patients with primary and secondary Sjögren’s syndrome. Scand J Rheumatol
1986;15:333–9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3798049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjögren syndrome. Arch Intern Med
2004; 164:1275–84</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15226160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Youinou P, Pennec YL, Katsikis P, et al. . Raynaud’s phenomenon in primary Sjögren’s syndrome. Br J Rheumatol
1990;29:205–7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2357503</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>García-Carrasco M, Siso A, Ramos-Casals M, et al. . Raynaud’s phenomenon in primary Sjögren’s syndrome. Prevalence and clinical characteristics in a series of 320 patients. J Rheumatol
2002; 29:726–30</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11950013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Papiris SA, Maniati M, Constantopoulos SH, et al. . Lung involvement in primary Sjögren’s syndrome is mainly related to the small airway disease. Ann Rheum Dis
1999;58:61–4</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1752755</ArticleId>
            <ArticleId IdType="pubmed">10343542</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Papiris SA, Tsonis IA, Moutsopoulos HM. Sjögren’s syndrome. Semin Respir Crit Care Med
2007;28:459–71</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17764063</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hatzis GS, Fragoulis GE, Karatzaferis A, et al. . Prevalence and longterm course of primary biliary cirrhosis in primary Sjögren’s syndrome. J Rheumatol
2008;35:2012–6</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18709690</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maripuri S, Grande JP, Osborn TG, et al. . Renal involvement in primary Sjögren’s syndrome: a clinicopathologic study. Clin J Am Soc Nephrol
2009;4:1423–31</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2736689</ArticleId>
            <ArticleId IdType="pubmed">19679669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moutsopoulos HM, Cledes J, Skopouli FN, et al. . Nephrocalcinosis in Sjögren’s syndrome: a late sequela of renal tubular acidosis. J Intern Med
1991;230:187–91</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1865172</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goules AV, Tatouli IP, Moutsopoulos HM, et al. . Clinically significant renal involvement in primary Sjögren’s syndrome: clinical presentation and outcome. Arthritis Rheum
2013;65:2945–53</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24166794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caramaschi P, Biasi D, Caimmi C, et al. . The co-occurrence of Hashimoto thyroiditis in primary Sjögren’s syndrome defines a subset of patients with milder clinical phenotype. Rheumatol Int
2013;33:1271–5</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23124734</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moutsopoulos HM, Balow JE, Lawley TJ, et al. . Immune complex glomerulonephritis in sicca syndrome. Am J Med
1978;64:955–60</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">148842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alexander EL. Neurologic disease in Sjögren’s syndrome: mononuclear inflammatory vasculopathy affecting central/peripheral nervous system and muscle. A clinical review and update of immunopathogenesis. Rheum Dis Clin North Am
1993;19:869–908</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8265827</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wandinger KP, Stangel M, Witte T, et al. . Autoantibodies against aquaporin-4 in patients with neuropsychiatric systemic lupus erythematosus and primary Sjögren’s syndrome. Arthritis Rheum
2010;62:1198–200</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20131265</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baimpa E, Dahabreh IJ, Voulgarelis M, et al. . Hematologic manifestations and predictors of lymphoma development in primary Sjögren syndrome: clinical and pathophysiologic aspects. Medicine (Baltimore)
2009;88:284–93</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19745687</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Theander E, Vasaitis L, Baecklund E, et al. . Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjögren’s syndrome. Ann Rheum Dis
2011;70:1363–8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3128323</ArticleId>
            <ArticleId IdType="pubmed">21715359</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hackett KL, Newton JL, Frith J, et al. . Impaired functional status in primary Sjögren’s syndrome. Arthritis Care Res (Hoboken)
2012; 64:1760–4</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23111856</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karaiskos D, Mavragani CP, Sinno MH, et al. . Psychopathological and personality features in primary Sjögren’s syndrome–associations with autoantibodies to neuropeptides. Rheumatology (Oxford)
2010;49:1762–9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20525741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drosos AA, Angelopoulos NV, Liakos A, et al. . Personality structure disturbances and psychiatric manifestations in primary Sjögren’s syndrome. J Autoimmun
1989;2:489–93</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2789650</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Strömbeck B, Theander E, Jacobsson LT. Assessment of fatigue in primary Sjögren’s syndrome: the Swedish version of the Profile of Fatigue. Scand J Rheumatol
2005;34:455–9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16393768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Theander L, Strömbeck B, Mandl T, et al. . Sleepiness or fatigue? Can we detect treatable causes of tiredness in primary Sjögren’s syndrome?
Rheumatology (Oxford)
2010;49:1177–83</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20308122</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gudbjörnsson B, Broman JE, Hetta J, et al. . Sleep disturbances in patients with primary Sjögren’s syndrome. Br J Rheumatol
1993;32:1072–6</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8252317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karaiskos D, Mavragani CP, Makaroni S, et al. . Stress, coping strategies and social support in patients with primary Sjögren’s syndrome prior to disease onset: a retrospective case-control study. Ann Rheum Dis
2009;68:40–6</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18276740</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wöhrer S, Troch M, Streubel B, et al. . MALT lymphoma in patients with autoimmune diseases: a comparative analysis of characteristics and clinical course. Leukemia
2007;21:1812–8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17554381</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nocturne G, Pavy S, Lazure T, et al. . IgG4 multiorgan lymphoproliferative syndrome as a differential diagnosis of primary Sjögren’s syndrome in men?
Ann Rheum Dis
2011;70:2234–5</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21646415</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mavragani CP, Skopouli FN, Moutsopoulos HM. Increased prevalence of antibodies to thyroid peroxidase in dry eyes and mouth syndrome or sicca asthenia polyalgia syndrome. J Rheumatol
2009;36:1626–30</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19605678</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mavragani CP, Fragoulis GE, Rontogianni D, et al. . Elevated IgG serum levels among primary Sjögren’s syndrome patients: Do they unmask underlying IgG4-Related disease?
Arthritis Care Res. 2013. 
10.1002/acr.22216</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/acr.22216</ArticleId>
            <ArticleId IdType="pubmed">25100215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liew MS, Zhang M, Kim E, et al. . Prevalence and predictors of Sjögren’s syndrome in a prospective cohort of patients with aqueous-deficient dry eye. Br J Ophthalmol
2012;96:1498–503</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23001257</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dafni UG, Tzioufas AG, Staikos P, et al. . Prevalence of Sjögren’s syndrome in a closed rural community. Ann Rheum Dis
1997;56: 521–5</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1752451</ArticleId>
            <ArticleId IdType="pubmed">9370875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vitali C, Moutsopoulos HM, Bombardieri S. The European Community Study Group on diagnostic criteria for Sjögren’s syndrome. Sensitivity and specificity of tests for ocular and oral involvement in Sjögren’s syndrome. Ann Rheum Dis
1994;53:637–47</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1005429</ArticleId>
            <ArticleId IdType="pubmed">7979575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stewart CM, Bhattacharyya I, Berg K, et al. . Labial salivary gland biopsies in Sjögren’s syndrome: still the gold standard?
Oral Surg Oral Med Oral Pathol Oral Radiol Endod
2008;106:392–402</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18602295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Venables PJ, Shattles W, Pease CT, et al. . Anti-La (SS-B): A diagnostic criterion for Sjögren’s syndrome?
Clin Exp Rheumatol
1989;7:181–4</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2736832</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vitali C, Bombardieri S, Jonsson R, et al. . Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis
2002;61:554–8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1754137</ArticleId>
            <ArticleId IdType="pubmed">12006334</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shiboski SC, Shiboski CH, Criswell L, et al. . American College of Rheumatology classification criteria for Sjögren’s syndrome: a data-driven, expert consensus approach in the Sjögren’s International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken)
2012;64:475–87</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3349440</ArticleId>
            <ArticleId IdType="pubmed">22563590</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mavragani CP, Moutsopoulos HM. Conventional therapy of Sjögren’s syndrome. Clin Rev Allergy Immunol
2007;32:284–91</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17992595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alves MB, Motta AC, Messina WC, et al. . Saliva substitute in xerostomic patients with primary Sjögren’s syndrome: a single-blind trial. Quintessence Int
2004;35:392–6</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15130080</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aragona P, Papa V, Micali A, et al. . Long term treatment with sodium hyaluronate-containing artificial tears reduces ocular surface damage in patients with dry eye. Br J Ophthalmol
2002;86:181–4</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1771021</ArticleId>
            <ArticleId IdType="pubmed">11815344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Condon PI, McEwen CG, Wright M, et al. . Double blind, randomised, placebo controlled, crossover, multicentre study to determine the efficacy of a 0.1% (w/v) sodium hyaluronate solution (Fermavisc) in the treatment of dry eye syndrome. Br J Ophthalmol
1999;83:1121–4</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1722832</ArticleId>
            <ArticleId IdType="pubmed">10502570</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McDonald CC, Kaye SB, Figueiredo FC, et al. . A randomised, crossover, multicentre study to compare the performance of 0.1% (w/v) sodium hyaluronate with 1.4% (w/v) polyvinyl alcohol in the alleviation of symptoms associated with dry eye syndrome. Eye (Lond)
2002;16:601–7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12194076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toda I, Shinozaki N, Tsubota K. Hydroxypropyl methylcellulose for the treatment of severe dry eye associated with Sjögren’s syndrome. Cornea
1996;15:120–8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8925658</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sall K, Stevenson OD, Mundorf TK, et al. . Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology
2000;107:631–9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10768324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ramos-Casals M, Tzioufas AG, Stone JH, et al. . Treatment of primary Sjögren syndrome: a systematic review. JAMA
2010; 304:452–60</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20664046</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marsh P, Pflugfelder SC. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren syndrome. Ophthalmology
1999;106:811–6</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10201607</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hersh PS, Rice BA, Baer JC, et al. . Topical nonsteroidal agents and corneal wound healing. Arch Ophthalmol
1990;108:577–83</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2322160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vivino FB, Minerva P, Huang CH, et al. . Corneal melt as the initial presentation of primary Sjögren’s syndrome. J Rheumatol
2001;28:379–82</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11246683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cardozo L, Bachmann G, McClish D, et al. . Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol
1998;92:722–7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9764689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meijer JM, Meiners PM, Vissink A, et al. . Effectiveness of rituximab treatment in primary Sjögren’s syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum
2010;62:960–8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20131246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mavragani CP, Moutsopoulos NM, Moutsopoulos HM. The management of Sjögren’s syndrome. Nat Clin Pract Rheumatol
2006;2:252–61</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16932698</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ramos-Casals M, Brito-Zeron P, Siso-Almirall A, et al. . Topical and systemic medications for the treatment of primary Sjögren’s syndrome. Nat Rev Rheumatol
2012;8:399–411</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22549247</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fox RI, Dixon R, Guarrasi V, et al. . Treatment of primary Sjögren’s syndrome with hydroxychloroquine: a retrospective, open-label study. Lupus
1996;5(Suppl 1):S31–6</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8803908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gottenberg JE, Cinquetti G, Larroche C, et al. . Efficacy of rituximab in systemic manifestations of primary Sjögren’s syndrome: results in 78 patients of the Auto Immune and Rituximab registry. Ann Rheum Dis
2013;72:1026–31</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23264337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skopouli FN, Jagiello P, Tsifetaki N, et al. . Methotrexate in primary Sjögren’s syndrome. Clin Exp Rheumatol
1996;14:555–8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8913659</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mariette X, Ravaud P, Steinfeld S, et al. . Inefficacy of infliximab in primary Sjögren’s syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren’s Syndrome (TRIPSS). Arthritis Rheum
2004;50:1270–6</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15077311</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mavragani CP, Niewold TB, Moutsopoulos NM, et al. . Augmented interferon-alpha pathway activation in patients with Sjögren’s syndrome treated with etanercept. Arthritis Rheum
2007;56:3995–4004</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2737264</ArticleId>
            <ArticleId IdType="pubmed">18050196</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dass S, Bowman SJ, Vital EM, et al. . Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis
2008;67:1541–4</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18276741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mekinian A, Ravaud P, Hatron PY, et al. . Efficacy of rituximab in primary Sjögren’s syndrome with peripheral nervous system involvement: results from the AIR registry. Ann Rheum Dis
2012; 71:84–7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21926185</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mariette X, Gottenberg JE. Pathogenesis of Sjögren’s syndrome and therapeutic consequences. Curr Opin Rheumatol
2010;22: 471–7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20671520</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seror R, Sordet C, Guillevin L, et al. . Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren’s syndrome. Ann Rheum Dis
2007;66:351–7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1856024</ArticleId>
            <ArticleId IdType="pubmed">16950808</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
